CiMaas focuses on the development of cellular immunotherapy for the treatment of cancer. One of these therapies is based on healthy donor derived Natural Killer cells to treat cancer patients.
CiMaas BV, a company developing cellular immunotherapy for cancer, and PharmaCell BV, a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, have agreed to collaborate in the clinical development of CiMaas’ products.
Dr Yvo Graus, PhD, MBA, will join the management team of CiMaas. Yvo Graus is an immunologist and has extensive experience in biotechnology. Through his activities at Genmab, Yvo gained great experience in product development from bench to bedside. He worked on the development of products in the laboratory to making them applicable in patients…. Read more »
Drs D.A. van den Noort, MD, and member of the Board of Directors of Bioseutica, has been appointed as first member of the Supervisory Board of CiMaas. Mister van den Noort has tremendous experience in the pharmaceutical industry and is well acquainted with investment instruments in Biotech start-ups. Daan van den Noort: “CiMaas is an… Read more »
Out of 75 applicants, 20 young companies have been nominated to receive an innovation award in November 2015. CiMaas is one of these 20 companies that is in the running for 1 of the 5 awards to be given by the Province of Limburg. For further information on the Innovaward see: innovaward.nl Specifically for CiMaas:… Read more »